Abstract
Allosteric drugs bind to sites which are usually less conserved evolutionarily as compared to orthosteric sites. As such, they can discriminate between closely related proteins, have fewer side effects, and a consequent lower concentration can convey a lesser likelihood of receptor desensitization. However, an allosteric mode of action may also make the results of preclinical and animal experiments less predictive. The sensitivity of the allosteric consequences to the environment further increases the importance of accounting for patient population diversity. Even subtle differences in protein sequence, in cellular metabolic states or in target tissues, can result in different outcomes. This mini-hot-topic issue of CTMC showcases some successes and challenges of allosteric drug development through the examples of seventransmembrane (GPCR), AMPA, NMDA and metabotropic glutamate receptors, as well as the morpheein model of allosterism involved in inherent metabolic errors. Finally, the development of allo-network drugs, which are allosteric drugs acting indirectly on the neighborhood of the pharmacological target in protein-protein interaction or signaling networks, is described.
Keywords: Allo-network drugs, allosteric drugs, glutamatergic transmission, GPCR receptors, networks, quaternary structure, SAR landscapes, schizophrenia
Current Topics in Medicinal Chemistry
Title:Editorial (Hot Topic: From Allosteric Drugs to Allo-Network Drugs: State of the Art and Trends of Design, Synthesis and Computational Methods)
Volume: 13 Issue: 1
Author(s): Peter Csermely, Ruth Nussinov and Andras Szilagyi
Affiliation:
Keywords: Allo-network drugs, allosteric drugs, glutamatergic transmission, GPCR receptors, networks, quaternary structure, SAR landscapes, schizophrenia
Abstract: Allosteric drugs bind to sites which are usually less conserved evolutionarily as compared to orthosteric sites. As such, they can discriminate between closely related proteins, have fewer side effects, and a consequent lower concentration can convey a lesser likelihood of receptor desensitization. However, an allosteric mode of action may also make the results of preclinical and animal experiments less predictive. The sensitivity of the allosteric consequences to the environment further increases the importance of accounting for patient population diversity. Even subtle differences in protein sequence, in cellular metabolic states or in target tissues, can result in different outcomes. This mini-hot-topic issue of CTMC showcases some successes and challenges of allosteric drug development through the examples of seventransmembrane (GPCR), AMPA, NMDA and metabotropic glutamate receptors, as well as the morpheein model of allosterism involved in inherent metabolic errors. Finally, the development of allo-network drugs, which are allosteric drugs acting indirectly on the neighborhood of the pharmacological target in protein-protein interaction or signaling networks, is described.
Export Options
About this article
Cite this article as:
Csermely Peter, Nussinov Ruth and Szilagyi Andras, Editorial (Hot Topic: From Allosteric Drugs to Allo-Network Drugs: State of the Art and Trends of Design, Synthesis and Computational Methods), Current Topics in Medicinal Chemistry 2013; 13 (1) . https://dx.doi.org/10.2174/1568026611313010002
DOI https://dx.doi.org/10.2174/1568026611313010002 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patent Selections:
Recent Patents on Anti-Infective Drug Discovery Discovery and Optimization of 1-(4-chloro-3-(trifluoromethyl)- phenyl)-3-(2-(amino)pyridin-3-yl)ureas as Novel KDR Kinase Inhibitors
Medicinal Chemistry COVID-19-associated Coagulopathy: Role of Vitamins D and K
Current Pharmaceutical Biotechnology The Chemokine System as a Therapeutic Target in Autoimmune Thyroid Diseases: A Focus on the Interferon-γ Inducible Chemokines and their Receptor
Current Pharmaceutical Design Human ACE-2, MCP1 and micro-RNA 146 as Novel Markers for COVID- 19 Affection and Severity
Infectious Disorders - Drug Targets Flavonoids as Anticancer Agents: Recent Progress and State of the Art?
Current Organic Chemistry Docking-Based Virtual Screening: Recent Developments
Combinatorial Chemistry & High Throughput Screening Advances in Drug Discovery based on Genomics, Proteomics and Bioinformatics (Part II)
Current Topics in Medicinal Chemistry Computational Prediction of Properties and Analysis of Molecular Phylogenetics of Polyketide Synthases in Three Species of Actinomycetes
Medicinal Chemistry Pharmacological Strategies for COVID-19 - A Review of the Most Promising Repurposed Antiviral Drugs
Infectious Disorders - Drug Targets COVID-19 Pandemic: How can Computer-assisted Methods help to Rein in this Global Menace?
Current Computer-Aided Drug Design Recent Review on Subclass B1 Metallo-β-lactamases Inhibitors: Sword for Antimicrobial Resistance
Current Drug Targets Nonanolides of Natural Origin: Structure, Synthesis, and Biological Activity
Current Medicinal Chemistry Research and Patents on Coronavirus and COVID-19: A Review
Recent Patents on Nanotechnology Antiandrogens in Prostate Cancer Endocrine Therapy
Current Cancer Drug Targets The Undiscovered Potential of Essential Oils for Treating SARS-CoV-2 (COVID-19)
Current Pharmaceutical Design Microtubule Targeting Agents: A Benchmark in Cancer Therapy
Current Drug Therapy Pericytes Within A Pulmonary Neurovascular Unit in Coronavirus Disease 2019 Elicited Pathological Changes
Current Neurovascular Research New Genetic and Pharmacological Treatments for Cystic Fibrosis
Current Pediatric Reviews Plant Plastid Engineering
Current Genomics